--- title: "Enicepatide | PepTracker Pro" url: https://peptrackerpro.com/peptides/enicepatide description: "An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Enicepatide Medium Evidence An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity. Aliases CT-388 +3 more Evidence Medium Evidence Last Updated 2026-06-04 Reading Time 3 min ## What It Is Enicepatide (development codes CT-388 and RO7795068) is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist developed by Roche and its U.S. subsidiary Genentech for the treatment of obesity and overweight, including people with associated comorbidities such as type 2 diabetes. The molecule originated from Carmot Therapeutics, which Roche acquired in 2023, and is engineered as a cAMP signal-biased agonist: it activates both the GLP-1 and GIP receptors potently but with minimal to no beta-arrestin recruitment at either receptor. Because beta-arrestin drives receptor internalization and desensitization, this biased signaling is designed to limit receptor down-regulation and produce more prolonged pharmacological activity. In the Phase 2 CT388-103 dose-finding trial, which enrolled 469 adults living with obesity or overweight plus at least one weight-related comorbidity, enicepatide delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand) at the highest 24 mg dose, with no weight-loss plateau reached by week 48; the treatment-regimen estimand showed 18.3% placebo-adjusted weight loss (p<0.001). A clear dose-response was observed, and at 24 mg, 95.7% of participants achieved at least 5% weight loss, 87% at least 10%, 47.8% at least 20%, and 26.1% at least 30%. Among participants who were prediabetic at baseline, 73% returned to normal blood glucose by week 48 on the 24 mg dose. The therapy was generally well tolerated, with most gastrointestinal adverse events mild to moderate and a 5.9% discontinuation rate due to adverse events in the enicepatide arms versus 1.3% on placebo. Roche reported positive topline results in late January 2026 and is moving enicepatide into Phase 3 development. Late-breaking 48-week Phase 2 data (abstract 2813-LB, Lingvay I et al.) are being presented at the American Diabetes Association (ADA) 2026 Scientific Sessions (June 5-8, New Orleans). Roche also plans to initiate a Phase 2 multi-arm trial of enicepatide and petrelintide fixed-dose combinations around mid-2026, positioning enicepatide both as a standalone obesity medicine and as a backbone for combination therapy. Also known as: CT-388, RO7795068, Genentech CT-388, enicepatide (CT-388) ## Regulatory Status Investigational Positive Phase 2 (CT388-103) results reported January 2026; advancing to Phase 3. Not approved in any jurisdiction. Effective: 2026 View FDA Source (https://www.roche.com/media/releases/med-cor-2026-01-27) ## Why Researchers Study It Enicepatide is closely watched because its Phase 2 weight-loss magnitude - up to roughly 22.5% placebo-adjusted at 48 weeks without a plateau - is among the largest reported for an incretin-based therapy, rivaling or exceeding established dual and triple agonists. Its cAMP signal-biased design is a novel pharmacological approach intended to reduce receptor desensitization and sustain activity, and researchers study it both as a potential best-in-class standalone obesity drug and as a backbone for fixed-dose combination with the amylin analog petrelintide. The Roche/Genentech program, built on the Carmot acquisition, also signals major commercial conviction in next-generation GLP-1/GIP biology. ## Proposed Mechanisms - Co-agonizes GLP-1 and GIP receptors to reduce appetite, improve satiety, and enhance glucose control - cAMP signal-biased design activates receptors with minimal beta-arrestin recruitment - Reduced receptor internalization and desensitization aims to prolong pharmacological activity - Long-acting profile enables once-weekly subcutaneous dosing - Positioned as a potential backbone for combination with the amylin analog petrelintide ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 2, CT388-103) | 469 adults with obesity or overweight plus >=1 weight-related comorbidity, 48 weeks | Up to 22.5% placebo-adjusted mean weight loss at 48 weeks (efficacy estimand) at 24 mg, no plateau; 18.3% by treatment-regimen estimand (p<0.001); at 24 mg, 87% achieved >=10% and 26.1% achieved >=30% weight loss | Source: https://www.gene.com/media/press-releases/15097/2026-01-26/genentech-announces-positive-phase-ii-re | | Human (Phase 2, glycemic outcomes) | Prediabetic participants at baseline, 24 mg dose | 73% returned to normal blood glucose by week 48; discontinuation due to adverse events 5.9% (enicepatide) vs 1.3% (placebo), GI events mostly mild-to-moderate | Source: https://www.healio.com/news/endocrinology/20260127/adults-with-obesity-lost-up-to-225-of-weight-at-48-weeks-with-novel-drug | | Development / regulatory | Roche/Genentech obesity program (originated at Carmot Therapeutics) | Positive Phase 2 topline reported Jan 2026; advancing to Phase 3; late-breaking 48-week data (2813-LB) at ADA 2026; Phase 2 enicepatide + petrelintide combination trial planned mid-2026 | Source: https://www.globenewswire.com/news-release/2026/06/01/3303993/0/en/roche-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-association-s-2026-scientific-sessions.html | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Researching Enicepatide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=enicepatide) ## Safety & Cautions - Investigational; not approved in any jurisdiction - Only Phase 2 efficacy and safety data reported to date; long-term outcomes unknown - Full peer-reviewed CT388-103 publication not yet available - Gastrointestinal adverse events and a higher AE-related discontinuation rate than placebo were observed - Available only through clinical trial enrollment; not an FDA-approved or compounding-eligible peptide ## Comparisons See how Enicepatide compares to related peptides: Enicepatide vs Maridebart Cafraglutide (MariTide): https://peptrackerpro.com/compare/enicepatide-vs-maridebart-cafraglutide Enicepatide vs Petrelintide: https://peptrackerpro.com/compare/enicepatide-vs-petrelintide Enicepatide vs Retatrutide: https://peptrackerpro.com/compare/enicepatide-vs-retatrutide Enicepatide vs Semaglutide: https://peptrackerpro.com/compare/enicepatide-vs-semaglutide Enicepatide vs Tirzepatide: https://peptrackerpro.com/compare/enicepatide-vs-tirzepatide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Roche to present new data advancing its obesity portfolio at the ADA 2026 Scientific Sessions (Jun 1, 2026) PubMed (https://www.globenewswire.com/news-release/2026/06/01/3303993/0/en/roche-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-association-s-2026-scientific-sessions.html) 2. [2] Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity (Jan 26, 2026) PubMed (https://www.gene.com/media/press-releases/15097/2026-01-26/genentech-announces-positive-phase-ii-re) 3. [3] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity (Jan 27, 2026) PubMed (https://www.roche.com/media/releases/med-cor-2026-01-27) 4. [4] Adults with obesity lost up to 22.5% of weight at 48 weeks with novel drug (Healio, Jan 27, 2026) PubMed (https://www.healio.com/news/endocrinology/20260127/adults-with-obesity-lost-up-to-225-of-weight-at-48-weeks-with-novel-drug) 5. [5] Roche moves obesity drug to pivotal trials after mid-stage success (STAT, Jan 27, 2026) PubMed (https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/) 6. [6] A Study of CT-388 in Participants Who Are Overweight or Obese (Roche ForPatients) PubMed (https://forpatients.roche.com/en/trials/metabolic-disorder/obesity/a-study-of-ct-388-in-participants-who-are-overweight-or-91515.html) ### Keep researching in the app - Log Enicepatide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=enicepatide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### Petrelintide Medium Evidence A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/petrelintide \+ Compare: https://peptrackerpro.com/compare?select=petrelintide Track in App: https://app.peptrackerpro.com/?add=petrelintide ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Enicepatide", "description": "An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity.", "url": "https://peptrackerpro.com/peptides/enicepatide", "lastReviewed": "2026-06-04", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Enicepatide", "item": "https://peptrackerpro.com/peptides/enicepatide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following next-generation GLP-1/GIP obesity therapies beyond tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Enicepatide is a research peptide studied in preclinical models. An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity." } }, { "@type": "Question", "name": "Those interested in high-magnitude weight-loss candidates in late-stage development?", "acceptedAnswer": { "@type": "Answer", "text": "Enicepatide is a research peptide studied in preclinical models. An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity." } }, { "@type": "Question", "name": "Individuals tracking the Roche/Genentech and Carmot obesity pipeline?", "acceptedAnswer": { "@type": "Answer", "text": "Enicepatide is a research peptide studied in preclinical models. An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity." } }, { "@type": "Question", "name": "Healthcare providers monitoring signal-biased incretin agonists and combination strategies?", "acceptedAnswer": { "@type": "Answer", "text": "Enicepatide is a research peptide studied in preclinical models. An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity." } } ] } ] ```